The adoption of nintedanib in systemic sclerosis: the SENSCIS study

Teresa Bruni, Francesco Varone

Source: Breathe, 16 (2) e44; 10.1183/20734735.0005-2020
Journal Issue: June
Disease area: Interstitial lung diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Teresa Bruni, Francesco Varone. The adoption of nintedanib in systemic sclerosis: the SENSCIS study. Breathe, 16 (2) e44; 10.1183/20734735.0005-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The genetics of systemic sclerosis
Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension
Year: 2008


Clinical feature of systemic sclerosis associated with pulmonary hypertension: results of one center study
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008


Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicentered open-label study
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008

Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Year: 2019


Exercise limitation in systemic sclerosis
Source: Eur Respir J 2005; 26: Suppl. 49, 107s
Year: 2005

Clinical and laboratory features of systemic sclerosis with pulmonary involvement
Source: Eur Respir J 2001; 18: Suppl. 33, 512s
Year: 2001

Significance of pulmonary involvement in systemic sclerosis (SSc)– data from the German SSc-network
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Year: 2018



Etiologic factors in patients with systemic sclerosis
Source: Eur Respir J 2006; 28: Suppl. 50, 98s
Year: 2006

Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc)
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension
Year: 2019




Pulmonary involvement and exercise limitation in patients with systemic sclerosis
Source: Eur Respir J 2004; 24: Suppl. 48, 53s
Year: 2004

Experimental modeling of lung involvement due to systemic sclerosis.
Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Year: 2020


Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study
Source: ERJ Open Res, 4 (1) 00135-2017; 10.1183/23120541.00135-2017
Year: 2018



Pulmonary involvement in systemic sclerosis
Source: Eur Respir Monogr 2019; 86: 90-105
Year: 2019


Evidence-based consensus recommendations for the identification and management of interstitial lung disease in systemic sclerosis
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Year: 2019

Pulmonary hypertension in systemic sclerosis: different phenotypes
Source: Eur Respir Rev, 26 (145) 170056; 10.1183/16000617.0056-2017
Year: 2017



Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study
Source: Eur Respir J, 53 (2) 1800081; 10.1183/13993003.00081-2018
Year: 2019



Incidence of pulmonary arterial hypertension related to systemic sclerosis: a 3-year nationwide longitudinal study
Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases
Year: 2008


Induced sputum in systemic sclerosis: A new potential for biomarkers in SSc
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019


Pulmonary arterial hypertension: screening challenges in systemic sclerosis and future directions
Source: Eur Respir J, 49 (5) 1700522; 10.1183/13993003.00522-2017
Year: 2017